Cargando…

A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19

OBJECTIVE: To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. PATIENTS AND METHODS: A total of 1169 adults aged 18 years of age or older who tested positive i...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanda, Sanjeev, Toussaint, Loren, Vincent, Ann, Fischer, Karen M., Hurt, Ryan, Schroeder, Darrell R., Chacin Suarez, Audry S., Medina Inojosa, Jose R., O’Horo, John C., DeJesus, Ramona S., Abu Lebdeh, Haitham S., Mundi, Manpreet S., Iftikhar, Salma, Croghan, Ivana T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053748/
https://www.ncbi.nlm.nih.gov/pubmed/33855875
http://dx.doi.org/10.1177/21501327211010991
_version_ 1783680178984058880
author Nanda, Sanjeev
Toussaint, Loren
Vincent, Ann
Fischer, Karen M.
Hurt, Ryan
Schroeder, Darrell R.
Chacin Suarez, Audry S.
Medina Inojosa, Jose R.
O’Horo, John C.
DeJesus, Ramona S.
Abu Lebdeh, Haitham S.
Mundi, Manpreet S.
Iftikhar, Salma
Croghan, Ivana T.
author_facet Nanda, Sanjeev
Toussaint, Loren
Vincent, Ann
Fischer, Karen M.
Hurt, Ryan
Schroeder, Darrell R.
Chacin Suarez, Audry S.
Medina Inojosa, Jose R.
O’Horo, John C.
DeJesus, Ramona S.
Abu Lebdeh, Haitham S.
Mundi, Manpreet S.
Iftikhar, Salma
Croghan, Ivana T.
author_sort Nanda, Sanjeev
collection PubMed
description OBJECTIVE: To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. PATIENTS AND METHODS: A total of 1169 adults aged 18 years of age or older who tested positive in Mayo Clinic Rochester or the Mayo Clinic Midwest Health System between January 1 and May 23 of 2020. RESULTS: Patients were on average 43.9 years of age and 50.7% were female. Most patients were white (69.0%), and Blacks (23.4%) and Asians (5.8%) were also represented in larger numbers. Hispanics represented 16.3% of the sample. Just under half of patients were married (48.4%). Common comorbid conditions included: cardiovascular diseases (25.1%), dyslipidemia (16.0%), diabetes mellitus (11.2%), chronic obstructive pulmonary disease (6.6%), asthma (7.5%), and cancer (5.1%). All other comorbid conditions were less the 5% in prevalence. Data on 3 comorbidity indices are also available including the: DHHS multi-morbidity score, Charlson Comorbidity Index, and Mayo Clinic COVID-19 Risk Factor Score. CONCLUSION: In addition to managing the ever raging pandemic and growing death rates, it is equally important that we develop adequate resources for the investigation and understanding of COVID-19-related predictors and outcomes.
format Online
Article
Text
id pubmed-8053748
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80537482021-05-03 A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 Nanda, Sanjeev Toussaint, Loren Vincent, Ann Fischer, Karen M. Hurt, Ryan Schroeder, Darrell R. Chacin Suarez, Audry S. Medina Inojosa, Jose R. O’Horo, John C. DeJesus, Ramona S. Abu Lebdeh, Haitham S. Mundi, Manpreet S. Iftikhar, Salma Croghan, Ivana T. J Prim Care Community Health Pilot Studies OBJECTIVE: To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. PATIENTS AND METHODS: A total of 1169 adults aged 18 years of age or older who tested positive in Mayo Clinic Rochester or the Mayo Clinic Midwest Health System between January 1 and May 23 of 2020. RESULTS: Patients were on average 43.9 years of age and 50.7% were female. Most patients were white (69.0%), and Blacks (23.4%) and Asians (5.8%) were also represented in larger numbers. Hispanics represented 16.3% of the sample. Just under half of patients were married (48.4%). Common comorbid conditions included: cardiovascular diseases (25.1%), dyslipidemia (16.0%), diabetes mellitus (11.2%), chronic obstructive pulmonary disease (6.6%), asthma (7.5%), and cancer (5.1%). All other comorbid conditions were less the 5% in prevalence. Data on 3 comorbidity indices are also available including the: DHHS multi-morbidity score, Charlson Comorbidity Index, and Mayo Clinic COVID-19 Risk Factor Score. CONCLUSION: In addition to managing the ever raging pandemic and growing death rates, it is equally important that we develop adequate resources for the investigation and understanding of COVID-19-related predictors and outcomes. SAGE Publications 2021-04-15 /pmc/articles/PMC8053748/ /pubmed/33855875 http://dx.doi.org/10.1177/21501327211010991 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Pilot Studies
Nanda, Sanjeev
Toussaint, Loren
Vincent, Ann
Fischer, Karen M.
Hurt, Ryan
Schroeder, Darrell R.
Chacin Suarez, Audry S.
Medina Inojosa, Jose R.
O’Horo, John C.
DeJesus, Ramona S.
Abu Lebdeh, Haitham S.
Mundi, Manpreet S.
Iftikhar, Salma
Croghan, Ivana T.
A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
title A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
title_full A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
title_fullStr A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
title_full_unstemmed A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
title_short A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
title_sort midwest covid-19 cohort for the evaluation of multimorbidity and adverse outcomes from covid-19
topic Pilot Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053748/
https://www.ncbi.nlm.nih.gov/pubmed/33855875
http://dx.doi.org/10.1177/21501327211010991
work_keys_str_mv AT nandasanjeev amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT toussaintloren amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT vincentann amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT fischerkarenm amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT hurtryan amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT schroederdarrellr amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT chacinsuarezaudrys amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT medinainojosajoser amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT ohorojohnc amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT dejesusramonas amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT abulebdehhaithams amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT mundimanpreets amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT iftikharsalma amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT croghanivanat amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT nandasanjeev midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT toussaintloren midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT vincentann midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT fischerkarenm midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT hurtryan midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT schroederdarrellr midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT chacinsuarezaudrys midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT medinainojosajoser midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT ohorojohnc midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT dejesusramonas midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT abulebdehhaithams midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT mundimanpreets midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT iftikharsalma midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19
AT croghanivanat midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19